Showing results (51-60 of 100) with videos related to

Sort By:
Pageof 10
Diabetes & Vascular Disease Research|January 16, 2015
SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trialsSilvio E Inzucchi, Bernard Zinman, Christoph Wanner, et al.
Circulation. Heart Failure|June 6, 2019
Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart FailureJaved Butler, Faiez Zannad, David Fitchett, et al.
JACC. Heart Failure|July 30, 2021
Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes: Insights From the EMPA-REG OUTCOME TrialAbhinav Sharma, Anne Pernille Ofstad, Tariq Ahmad, et al.
European Heart Journal|January 29, 2016
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trialDavid Fitchett, Bernard Zinman, Christoph Wanner, et al.
Circulation|September 15, 2017
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney DiseaseChristoph Wanner, John M Lachin, Silvio E Inzucchi, et al.
The American Journal of Cardiology|November 10, 2010
Relation between hemoglobin level and recurrent myocardial ischemia in acute coronary syndromes detected by continuous electrocardiographic monitoringMelissa Rousseau, Raymond T Yan, Mary Tan, et al.
American Journal of Hypertension|May 6, 2020
Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME TrialJoão Pedro Ferreira, David Fitchett, Anne Pernille Ofstad, et al.
The American Journal of Cardiology|September 29, 2005
In-hospital revascularization and one-year outcome of acute coronary syndrome patients stratified by the GRACE risk scoreAndrew T Yan, Raymond T Yan, Mary Tan, et al.
The New England Journal of Medicine|June 15, 2016
Empagliflozin and Progression of Kidney Disease in Type 2 DiabetesChristoph Wanner, Silvio E Inzucchi, John M Lachin, et al.
American Heart Journal|January 6, 2005
Clinical trial--derived risk model may not generalize to real-world patients with acute coronary syndromeAndrew T Yan, Philip Jong, Raymond T Yan, et al.
Pageof 10